A Study of NB004 As Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: NB004 tablets
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT05036291
- Locations
- 🇺🇸
LSU-LCMC Health Cancer Center, New Orleans, Louisiana, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳National Cheng Kung University Hospital（NCKUH）, Tainan, Taiwan, China
A Study of NB003 in Patients with Advanced Malignancies
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Target Recruit Count
- 258
- Registration Number
- NCT04936178
- Locations
- 🇺🇸
Standford University, Stanford, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath